Hypofractionated Nodal Radiation Therapy for Breast Cancer Was Not Associated With Increased Patient-Reported Arm or Brachial Plexopathy Symptoms

Leong, Nelson; Truong, Pauline T.; Tankel, Keith; Kwan, Winkle; Weir, Lorna; Olivotto, Ivo A.

doi:10.1016/j.ijrobp.2017.07.043

Cited by 30 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are limited available data regarding the effects of hypofractionated regional nodal RT in breast RT. Reports from a randomised trial [16] , registry [17] and institutional [18] , [19] analyses showed that hypofractionation for nodal RT is safe and effective. In 2013, hypofractionated RT in breast + nodes was only 8%.…”

Section: Discussionmentioning

confidence: 99%

Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications

Batumalai

Delaney

Descallar

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

Highlights We evaluated the use of hypofractionation in breast radiotherapy in an Australian population-based cohort. Hypofractionation appears underused for breast radiotherapy in Australia over time. Variation in practice were observed by patient, tumour, sociodemographic and geographical factors. This study highlights that evidence-based practice will translate to reduced health care treatment costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications

Batumalai

Delaney

Descallar

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Deliver RT in 5 fractions for all patients requiring RT with node negative tumours that do not require a boost. Options include 28-30Gy in one weekly fraction over 5 weeks or 26Gy in 5 daily fractions over 1 week as per the FAST and FAST Forward trials, respectively [22][23][24] .…”

mentioning

confidence: 99%

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

on behalf of the editorial board of The Breast. on behalf of the editorial board of The Breast. AbstractThe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated disease outbreak seriously challenges globally all health care systems and professionals. Expert projections estimate that despite social distancing and lockdown being practiced, we have yet to feel the full impact of COVID-19. In this manuscript we provide guidance to prepare for the impact of COVID-19 pandemic on breast cancer patients and advise on how to triage, prioritize and organize diagnostic procedures, surgical, radiation and medical treatments.

show abstract

“…These calculations are supported clinically with no differences in cardiac mortality by treatment arm in the Canadian trial (n = 1234) and no reported cases of brachial plexopathy in the patients receiving regional nodal treatment in either HF or CF arms of the UK trials, nor in the Chinese PMRT Trial (described below) . Consistent with these prospective trial data, large population‐based studies have also found no increase in cardiac morbidity or mortality in patients treated with left‐sided HF local and local‐regional radiotherapy or patient‐reported arm or brachial plexopathy symptoms in patients treated with HF to the regional nodes …”

Section: Variable Adoption Of Hypofractionationmentioning

confidence: 58%

Hypofractionated radiation treatment for breast cancer: The time is now

Moran

Truong

2020

Breast J

Self Cite

View full text Add to dashboard Cite

While there is now Level I data with long‐term follow‐up supporting the routine use of hypofractionated (HF) whole‐breast radiation therapy (WBRT) after breast‐conserving surgery, its adoption has been slow and variable. This article will review the literature supporting the efficacy and safety of hypofractionated radiation for breast cancer, discuss the radiobiological rationale specific to breast tumors, and make an argument for justifying the routine adoption of shorter, HF‐WBRT courses when delivering breast radiation. Data using HF with regional nodal irradiation and in the post‐mastectomy setting will also be reviewed. The aim is to provide an in‐depth understanding of the use of hypofractionated radiation therapy for breast cancer, its applicability, and topics warranting future research.

show abstract

Hypofractionated Nodal Radiation Therapy for Breast Cancer Was Not Associated With Increased Patient-Reported Arm or Brachial Plexopathy Symptoms

Cited by 30 publications

References 37 publications

Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications

Variation in the use of radiotherapy fractionation for breast cancer: Survival outcome and cost implications

Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic

Hypofractionated radiation treatment for breast cancer: The time is now

Contact Info

Product

Resources

About